Patent Protects Novel Application of Gedeptin Therapy Across Multiple Solid Tumor Types; Supports Expansion of Gedeptin ...
Phase 1/2 Trial Confirms Safety With Repeated Dosing Supporting Further Development in Early-stage Disease and Combination Treatment Settings ATLANTA, GA - December 8, 2025 (NEWMEDIAWIRE) - GeoVax ...
The regulator has received reports that a group of patients treated with Adzynma had neutralizing antibodies against the protein the therapy replaces. The FDA is investigating adverse events, ...
Abstract: Large language models (LLMs) and foundation models have been recently touted as a game-changer for 6 G systems. However, recent efforts on LLMs for wireless networks are limited to a direct ...
To manage the finances of CAR-T therapies, which can cost up to $1 million each, health systems are increasingly using “pay for performance” deals, according to a Nov. 17 article in Specialty Pharmacy ...
Abstract: This paper investigates dynamic event-triggered resilient formation control for nonlinear multi-agent systems under multi-channel Denial-of-Service (DoS) attacks. Unlike existing resilient ...
aDepartment of Rheumatology and Immunology, National Key Laboratory of Immunity and Inflammation, Changhai Hospital, Naval Medical University, Shanghai, China bDepartment of Rheumatology, Peking Union ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results